SCHEMBL6414707

SCHEMBL6414707

NN=C(c1cccc(O)c1)c1nc2nonc2nc1Nc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 2/20 0.40
MEN1 O00255 5/20 0.40
KMT2A Q03164 5/20 0.40
ABCG2 Q9UNQ0 3/20 0.40
TP53 P04637 3/20 0.40
MAPT P10636 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
CYP3A4 P08684 1/20 0.38
TSHR P16473 1/20 0.38
POLB P06746 2/20 0.37
NTSR1 P30989 1/20 0.36
RAD52 P43351 1/20 0.36
GFER P55789 1/20 0.36
GBA1 P04062 1/20 0.36
MAPK13 O15264 1/20 0.35
MAPK12 P53778 1/20 0.35
MAPK11 Q15759 1/20 0.35
MAPK14 Q16539 1/20 0.35
CDC25B P30305 1/20 0.35
TTBK1 Q5TCY1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6414695 1.00 PIM1 (0.40) PIM1MEN1KMT2AABCG2TP53
SCHEMBL6420021 0.90 SMN1; SMN2 (0.47) MEN1KMT2AABCG2TP53MAPT
SCHEMBL6502277 0.90 SMN1; SMN2 (0.47) MEN1KMT2AABCG2TP53MAPT
SCHEMBL6431156 0.89 TP53 (0.41) PIM1MEN1KMT2AABCG2TP53
SCHEMBL6431148 0.89 TP53 (0.41) PIM1MEN1KMT2AABCG2TP53
SCHEMBL6415954 0.88 RHOA (0.47) MEN1KMT2AABCG2MAPTCDC25B
SCHEMBL6415968 0.88 RHOA (0.47) MEN1KMT2AABCG2MAPTCDC25B
SCHEMBL6418416 0.87 PIM1 (0.40) PIM1MEN1KMT2AABCG2TP53
SCHEMBL6418422 0.87 PIM1 (0.40) PIM1MEN1KMT2AABCG2TP53
SCHEMBL6412976 0.86 MAPT (0.40) PIM1MEN1KMT2ATP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 PIM1 4383/4885MEN1 4392/4885KMT2A 3640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.